Vibostolimab

维博利单抗

Report date: 2026/05/13 20:02:10

Base Information

Drug NameVibostolimab
Drug Alias NameMK-7684
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineTaiwan +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLC
Inactive CompaniesMerck Sharp & Dohme Corp
Active IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG